ISB 2001
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 80 patients (estimated)
- Sponsors
- Ichnos Sciences SA
- Tags
- T Cell, B-Cell Maturation Antigen (BCMA), CD38
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1985
- NCT Identifier
- NCT05862012
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.